# Phase 2 Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined or Alone in Patients With Essential Hypetension

Study · id `cardio:ct-nct04488978` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04488978](<https://clinicaltrials.gov/study/NCT04488978>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04488978

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 440 participants.

## Technical summary

Registry record NCT04488978. Randomized; quadruple masking; primary purpose treatment. Start 2020-05-21 (actual); primary completion 2021-11-09 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 440 participants (enrolled count; ClinicalTrials.gov record NCT04488978, source copy `cardio:ctgov-nct04488978-2022-06-30`, retrieved 2026-10-26)
- Started: 2020-05-21 (actual) (ClinicalTrials.gov record NCT04488978, source copy `cardio:ctgov-nct04488978-2022-06-30`, retrieved 2026-10-26)
- Primary completion: 2021-11-09 (actual) (ClinicalTrials.gov record NCT04488978, source copy `cardio:ctgov-nct04488978-2022-06-30`, retrieved 2026-10-26)
- Completion: 2021-11-09 (actual) (ClinicalTrials.gov record NCT04488978, source copy `cardio:ctgov-nct04488978-2022-06-30`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT04488978, source copy `cardio:ctgov-nct04488978-2022-06-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04488978-2022-06-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: Phase 2 Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined or Alone in Patients With Essential Hypetension
- Condition: Essential Hypertension
- Intervention (Drug): Irbesartan/Amlodipine
- Lead sponsor: Handok Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Handok Inc. (`cardio:org-handok-inc`)

## Provenance

Content hash: 9a8d3b2d8282397bab90316ccfcbe2d3f927fa73af08e9812361dac364b730a2
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
